assembly biosciences (NASDAQ:ASMB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

19

assembly biosciences (NASDAQ:ASMB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 10, 2017, Dr. Miguel S. Barbosa, Chief Scientific Officer, Head of Microbiome Program, informed Assembly Biosciences, Inc. (the “Company”) that, due to family medical reasons, and unrelated to the Company or his performance, he intends to step down from all of his positions at the Company effective as of the close of business on October 31, 2017.

Dr. Barbosa will remain with the Company as a consultant in a strategic advisory role and to assist with the leadership transition. The terms of this arrangement have not been finalized. The Company will be initiating a search for a candidate to replace Dr. Barbosa. In the interim, Wayne K. Herber, Ph.D., Senior Vice President, Biological Manufacturing and Thomas E. Rollins, Chief Development Officer will jointly lead and oversee the Microbiome Program.


About assembly biosciences (NASDAQ:ASMB)

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing approximately two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of Hemoglobin C functions. The Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice (cGMP) conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile-infections.

An ad to help with our costs